New-onset anemia observed in the COMFORT-I trial2,3
| JAKAFI (n=155) | Placebo (n=151) | ||
|---|---|---|---|
| All Grades, % | Grades 3 and 4, % | All Grades, % | Grades 3 and 4, % |
| 96 | 45 | 87 | 19 |
For US Healthcare Professionals Only
46%
of patients receiving JAKAFI® (ruxolitinib) had anemia at baseline.† Mean Hb was 9.2 g/dL (range, 6.6 g/dL to 13.7 g/dL)1
Identification and management of new-onset anemia2
<1%
of patients receiving JAKAFI in the COMFORT-I study discontinued due to anemia2
COMFORT-I additional analysis
COMFORT trials post hoc pooled analysis
COMFORT-I additional analysis
BAT=best available therapy; CBC=complete blood count; COMFORT=COntrolled MyeloFibrosis study with ORal JAK inhibitor Treatment; CT=computed tomography; Hb=hemoglobin; JAK=Janus kinase; MF=myelofibrosis; MPN=myeloproliferative neoplasm; MRI=magnetic resonance imaging; OS=overall survival; RBC=red blood cell; SEM=standard error of the mean; SVR=spleen volume reduction; TSS=Total Symptom Score.
References: 1. Data on file. Incyte Corporation. Wilmington, DE. 2. JAKAFI/JAKAFI XR Prescribing Information. Wilmington, DE: Incyte Corporation. 3. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807. Supplementary appendix available at: https://www.nejm.org/doi/full/10.1056/nejmoa1110557. 4. Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015;100(4):479-488. 5. Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013;98(12):1865-1871. Supplementary appendix available at: https://haematologica.org/article/view/6861.
JAKAFI®/JAKAFI XR™ (ruxolitinib) is for treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
JAKAFI/JAKAFI XR is for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
JAKAFI/JAKAFI XR is for treatment of steroid‑refractory acute graft‑versus‑host disease (aGVHD) in adult and pediatric patients 12 years and older.
JAKAFI/JAKAFI XR is for treatment of chronic graft‑versus‑host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Please see Full Prescribing Information for JAKAFI/JAKAFI XR.